Bruce Conklin, an Investigator at Gladstone Institutes and a Professor in the Departments of Medicine, Ophthalmology, and Pharmacology at UCSF, is a leading figure in the pursuit of genetic disease cures through cutting-edge genome-engineering technology. His team's groundbreaking approach involves harnessing patient-specific induced pluripotent stem (iPS) cells to develop tissues derived from individuals carrying disease mutations. By employing CRISPR-based genome editing, they seek to correct these mutations and evaluate the impact using disease models established in iPS cells. Focusing on rare mutations with significant clinical potential, their proof-of-concept studies lay the foundation for broader applications in treating more common diseases. Driven by the vision of safe and cost-effective therapies, Conklin's work aims to bring tangible benefits to a wide spectrum of individuals.